{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T16:30:51Z","timestamp":1791477051507,"version":"4.3.4"},"reference-count":84,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T00:00:00Z","timestamp":1762300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T00:00:00Z","timestamp":1762300800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002839","name":"Charit\u00e9 - Universit\u00e4tsmedizin Berlin","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002839","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["EJNMMI radiopharm. chem."],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Radiopharmaceuticals offer targeted treatment by combining diagnostic or therapeutic radionuclides with biologically active molecules. Auranofin is the only Food and Drug Administration (FDA) approved gold(I) complex, originally developed for the treatment of rheumatoid arthritis. Recent evidence has highlighted its potential as an anticancer agent due to its ability to disrupt redox signaling, inhibit thioredoxin reductase, and impair glycolytic metabolism. This study aims to incorporate the true theranostic radionuclide\n                      <jats:sup>198<\/jats:sup>\n                      Au into the Auranofin scaffold and evaluate its impact in-vitro on cancer cells.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Carrier-added (c.a.)\n                      <jats:sup>198<\/jats:sup>\n                      Au was produced via neutron activation of\n                      <jats:sup>197<\/jats:sup>\n                      Au and subsequently converted into c.a. H [\n                      <jats:sup>198<\/jats:sup>\n                      Au] [AuCl\u2084]. Downscaled synthetic protocols were developed to sequentially generate c.a. [\n                      <jats:sup>198<\/jats:sup>\n                      Au] [Au(tht)Cl], [\n                      <jats:sup>198<\/jats:sup>\n                      Au] [Au(PEt\u2083)Cl], and [\n                      <jats:sup>198<\/jats:sup>\n                      Au]Auranofin. Radiochemical purity was evaluated using radio-high performance liquid chromatography, and in vitro stability was assessed in human serum albumin (HSA) over 72\u00a0h. Cytotoxic and metabolic activity were investigated in MCF7 and PC3 cancer cell lines using the cell viability assay 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT assay) and hexokinase assay, respectively. [\n                      <jats:sup>198<\/jats:sup>\n                      Au]Auranofin (c.a.) was obtained with a yield of 57.0\u2009\u00b1\u20093.2% and a radiochemical purity of 96.2\u2009\u00b1\u20093.9%. The compound demonstrated stability in human serum albumin, maintaining 96.9\u2009\u00b1\u20092.5% integrity over 72\u00a0h. In vitro studies revealed that c.a. [\n                      <jats:sup>198<\/jats:sup>\n                      Au]Auranofin exhibited enhanced cytotoxicity and significant hexokinase inhibition compared to its non-radioactive counterpart, while the precursor complexes remained non-toxic up to 20\u00a0\u00b5M. Viability loss was both concentration and radioactivity dependent across both cell lines.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      [\n                      <jats:sup>198<\/jats:sup>\n                      Au]Auranofin (c.a.) represents a stable and effective radiogold-based radiopharmaceutical agent, offering redox-targeted cytotoxicity alongside \u03b2\u207b emission mediated cell death and \u03b3 emission based imaging potential. These findings highlight c.a. [\n                      <jats:sup>198<\/jats:sup>\n                      Au]Auranofin as a promising radiogold-based theranostic candidate, offering dual capabilities in targeted cytotoxicity and nuclear imaging. While the in vitro results are encouraging, further in vivo and translational studies are warranted to fully evaluate its clinical potential in nuclear medicine guided cancer therapy.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s41181-025-00401-3","type":"journal-article","created":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T14:10:09Z","timestamp":1762351809000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Synthesis and in vitro characterization of [198Au]Auranofin"],"prefix":"10.1186","volume":"10","author":[{"given":"Punita","family":"Bhardwaj","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Frohner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Geppert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Gorges","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Winfried","family":"Brenner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guilhem","family":"Claude","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Spreckelmeyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,5]]},"reference":[{"key":"401_CR1","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1007\/s12672-021-00439-0","volume":"12","author":"FH Abdalbari","year":"2021","unstructured":"Abdalbari FH, Telleria CM. The gold complex auranofin: new perspectives for cancer therapy. Discov Oncol. 2021;12:42. https:\/\/doi.org\/10.1007\/s12672-021-00439-0.","journal-title":"Discov Oncol"},{"key":"401_CR2","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1007\/s42058-023-00128-7","volume":"6","author":"N Ahmed","year":"2023","unstructured":"Ahmed N, Zia M. Diagnostic modalities and radiopharmaceuticals with particular importance of technetium-99m (99mTc). Chin J Acad Radiol. 2023;6:143. https:\/\/doi.org\/10.1007\/s42058-023-00128-7.","journal-title":"Chin J Acad Radiol"},{"key":"401_CR3","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1039\/C2JA30109A","volume":"27","author":"A Albert","year":"2012","unstructured":"Albert A, Brauckmann C, Blaske F, Sperling M, Engelhard C, Karst U. Speciation analysis of the antirheumatic agent Auranofin and its thiol adducts by LC\/ESI-MS and LC\/ICP-MS. J Anal at Spectrom. 2012;27:975. https:\/\/doi.org\/10.1039\/C2JA30109A.","journal-title":"J Anal at Spectrom"},{"key":"401_CR4","doi-asserted-by":"publisher","first-page":"14561","DOI":"10.1039\/C7DT00383H","volume":"46","author":"AY Al-Yasiri","year":"2017","unstructured":"Al-Yasiri AY, Khoobchandani M, Cutler CS, Watkinson L, Carmack T, Smith CJ, et al. Mangiferin functionalized radioactive gold nanoparticles (MGF-198AuNPs) in prostate tumor therapy: green nanotechnology for production, in vivo tumor retention and evaluation of therapeutic efficacy. Dalton Trans. 2017;46:14561. https:\/\/doi.org\/10.1039\/C7DT00383H.","journal-title":"Dalton Trans"},{"key":"401_CR5","doi-asserted-by":"publisher","DOI":"10.3390\/ph17101394","volume":"17","author":"SC An","year":"2024","unstructured":"An SC, Jun HH, Kim KM, Kim I, Choi S, Yeo H, et al. Auranofin as a novel anticancer drug for anaplastic thyroid cancer. Pharmaceuticals (Basel). 2024;17:634. https:\/\/doi.org\/10.3390\/ph17101394.","journal-title":"Pharmaceuticals (Basel)"},{"key":"401_CR6","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/0883-2897(88)90109-2","volume":"15","author":"P Anderson","year":"1988","unstructured":"Anderson P, Vaughan ATM, Varley NR. Antibodies labeled with 199Au: potential of 199Au for radioimmunotherapy. Int J Radiat Appl Instrum Part B Nucl Med Biol. 1988;15:293. https:\/\/doi.org\/10.1016\/0883-2897(88)90109-2.","journal-title":"Int J Radiat Appl Instrum Part B Nucl Med Biol"},{"key":"401_CR7","unstructured":"A phase I\/IIa theranostic study of 64Cu-SAR-BBN and 67Cu-SAR-BBN for identification and treatment of GRPR-expressing metastatic castrate resistant prostate cancer in patients who are ineligible for therapy with 177Lu-PSMA-617. 2022."},{"key":"401_CR8","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1148\/15.3.723","volume":"115","author":"HL Atkins","year":"1975","unstructured":"Atkins HL, Lambrecht RM, Wolf AP, Ansari AN, Guillaume M. Distribution of various labeled thioglucoses in rodents. Radiology. 1975;115:723. https:\/\/doi.org\/10.1148\/15.3.723.","journal-title":"Radiology"},{"key":"401_CR9","first-page":"1","volume-title":"xPharm: the comprehensive pharmacology reference","author":"MJ Auranofin","year":"2007","unstructured":"Auranofin MJ. In: Enna SJ, Bylund DB, editors. xPharm: the comprehensive pharmacology reference. New York: Elsevier; 2007. p. 1\u20136."},{"key":"401_CR10","doi-asserted-by":"publisher","first-page":"5001","DOI":"10.2147\/IJN.S67333","volume":"9","author":"SM Axiak-Bechtel","year":"2014","unstructured":"Axiak-Bechtel SM, Upendran A, Lattimer JC, Kelsey J, Cutler CS, Selting KA, et al. Gum arabic-coated radioactive gold nanoparticles cause no short-term local or systemic toxicity in the clinically relevant canine model of prostate cancer. Int J Nanomed. 2014;9:5001. https:\/\/doi.org\/10.2147\/IJN.S67333.","journal-title":"Int J Nanomed"},{"key":"401_CR11","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s41181-023-00225-z","volume":"8","author":"A Baitullina","year":"2023","unstructured":"Baitullina A, Claude G, Sucena SF, Nisli E, Scholz C, Bhardwaj P, et al. Metallacages with 2,6-dipicolinoylbis(N,N-dialkylthioureas) as novel platforms in nuclear medicine for 68Ga, 177Lu and 198Au. EJNMMI Radiopharm Chem. 2023;8:40. https:\/\/doi.org\/10.1186\/s41181-023-00225-z.","journal-title":"EJNMMI Radiopharm Chem"},{"key":"401_CR12","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1021\/ic001073m","volume":"40","author":"SL Barnholtz","year":"2001","unstructured":"Barnholtz SL, Lydon JD, Huang G, Venkatesh M, Barnes CL, Ketring AR, et al. Syntheses and characterization of gold(III) tetradentate Schiff base complexes. X-ray crystal structures of [Au(sal2pn)]Cl2.5H2O and [Au(sal2en)]PF6. Inorg Chem. 2001;40:972. https:\/\/doi.org\/10.1021\/ic001073m.","journal-title":"Inorg Chem"},{"key":"401_CR13","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/S0969-8051(98)00023-7","volume":"25","author":"DE Berning","year":"1998","unstructured":"Berning DE, Katti KV, Volkert WA, Higginbotham CJ, Ketring AR. 198Au-labeled hydroxymethyl phosphines as models for potential therapeutic pharmaceuticals. Nucl Med Biol. 1998;25:577. https:\/\/doi.org\/10.1016\/S0969-8051(98)00023-7.","journal-title":"Nucl Med Biol"},{"key":"401_CR14","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/978-3-662-08608-7_8","volume-title":"Medical applications of nuclear physics","author":"K Bethge","year":"2004","unstructured":"Bethge K, Kraft G, Kreisler P, Walter G. Isotopes as diagnostic and therapeutic tools. In: Bethge K, Kraft G, Kreisler P, Walter G, editors. Medical applications of nuclear physics. Berlin Heidelberg, Berlin, Heidelberg: Springer; 2004. p. 141."},{"key":"401_CR15","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/0002-9343(86)90539-5","volume":"81","author":"C Bombardier","year":"1986","unstructured":"Bombardier C, Ware J, Russell IJ, Larson M, Chalmers A, Read JL, et al. Auranofin therapy and quality of life in patients with rheumatoid arthritis. Results of a multicenter trial. Am J Med. 1986;81:565. https:\/\/doi.org\/10.1016\/0002-9343(86)90539-5.","journal-title":"Am J Med"},{"key":"401_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.nucmedbio.2009.08.003","volume":"37","author":"BN Bottenus","year":"2010","unstructured":"Bottenus BN, Kan P, Jenkins T, Ballard B, Rold TL, Barnes C, et al. Gold(III) bis-thiosemicarbazonato complexes: synthesis, characterization, radiochemistry and X-ray crystal structure analysis. Nucl Med Biol. 2010;37:41. https:\/\/doi.org\/10.1016\/j.nucmedbio.2009.08.003.","journal-title":"Nucl Med Biol"},{"key":"401_CR17","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1016\/S0020-1693(00)92573-8","volume":"3","author":"O Bravo","year":"1969","unstructured":"Bravo O, Iwamoto RT. The chloro complexes of gold(I) in acetonitrile and comparison with those of copper(I) and silver(I). Inorg Chim Acta. 1969;3:663. https:\/\/doi.org\/10.1016\/S0020-1693(00)92573-8.","journal-title":"Inorg Chim Acta"},{"key":"401_CR18","doi-asserted-by":"publisher","first-page":"14337","DOI":"10.1021\/acs.iecr.8b02526","volume":"57","author":"R Chakravarty","year":"2018","unstructured":"Chakravarty R, Chakraborty S, Guleria A, Shukla R, Kumar C, Vimalnath Nair KV, et al. Facile one-pot synthesis of intrinsically radiolabeled and cyclic RGD conjugated 199Au nanoparticles for potential use in nanoscale brachytherapy. Ind Eng Chem Res. 2018;57:14337. https:\/\/doi.org\/10.1021\/acs.iecr.8b02526.","journal-title":"Ind Eng Chem Res"},{"key":"401_CR19","doi-asserted-by":"publisher","first-page":"8760","DOI":"10.1073\/pnas.1002143107","volume":"107","author":"N Chanda","year":"2010","unstructured":"Chanda N, Kattumuri V, Shukla R, Zambre A, Katti K, Upendran A, et al. Bombesin functionalized gold nanoparticles show in vitro and in vivo cancer receptor specificity. Proc Natl Acad Sci USA. 2010;107:8760. https:\/\/doi.org\/10.1073\/pnas.1002143107.","journal-title":"Proc Natl Acad Sci USA"},{"key":"401_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1039\/P29890000053","volume":"2","author":"SM Cottrill","year":"1989","unstructured":"Cottrill SM, Sharma HL, Dyson DB, Parish RV, McAuliffe CA. The role of the ligand in chrysotherapy: a kinetic study of 199Au- and 35S-labelled myocrisin and auranofin. J Chem Soc Perkin Trans. 1989;2:1\u201353. https:\/\/doi.org\/10.1039\/P29890000053.","journal-title":"J Chem Soc Perkin Trans"},{"key":"401_CR21","doi-asserted-by":"publisher","DOI":"10.1053\/j.semnuclmed.2025.01.007","author":"GM Currie","year":"2025","unstructured":"Currie GM, Rohren EM. Sharpening the blade of precision theranostics. Semin Nucl Med. 2025. https:\/\/doi.org\/10.1053\/j.semnuclmed.2025.01.007.","journal-title":"Semin Nucl Med"},{"key":"401_CR22","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.3390\/ph16121670","volume":"16","author":"G Davarci","year":"2023","unstructured":"Davarci G, W\u00e4ngler C, Eberhardt K, Geppert C, Schirrmacher R, Freudenberg R, et al. Radiosynthesis of stable 198Au-nanoparticles by neutron activation of \u03b1v\u03b23-specific AuNPs for therapy of tumor angiogenesis. Pharmaceuticals. 2023;16:1670.","journal-title":"Pharmaceuticals"},{"key":"401_CR23","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s40001-023-01627-0","volume":"29","author":"S Dhoundiyal","year":"2024","unstructured":"Dhoundiyal S, Srivastava S, Kumar S, Singh G, Ashique S, Pal R, et al. Radiopharmaceuticals: navigating the frontier of precision medicine and therapeutic innovation. Eur J Med Res. 2024;29:26. https:\/\/doi.org\/10.1186\/s40001-023-01627-0.","journal-title":"Eur J Med Res"},{"key":"401_CR24","doi-asserted-by":"publisher","first-page":"2718","DOI":"10.1002\/ejic.201300058","volume":"2013","author":"F Di Sarra","year":"2013","unstructured":"Di Sarra F, Fresch B, Bini R, Saielli G, Bagno A. Reactivity of auranofin with selenols and thiols \u2013 implications for the anticancer activity of gold(I) compounds. Eur J Inorg Chem. 2013;2013:2718. https:\/\/doi.org\/10.1002\/ejic.201300058.","journal-title":"Eur J Inorg Chem"},{"key":"401_CR25","unstructured":"Dotatate P. FDA approves 18F-fluciclovine and 68Ga-DOTATATE products. J Nucl Med. 2016;57."},{"key":"401_CR26","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.msec.2014.09.019","volume":"45","author":"Y Fazaeli","year":"2014","unstructured":"Fazaeli Y, Akhavan O, Rahighi R, Aboudzadeh MR, Karimi E, Afarideh H. In vivo SPECT imaging of tumors by 198,199Au-labeled graphene oxide nanostructures. Mater Sci Eng C Mater Biol Appl. 2014;45:196. https:\/\/doi.org\/10.1016\/j.msec.2014.09.019.","journal-title":"Mater Sci Eng C Mater Biol Appl"},{"key":"401_CR27","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.3390\/cancers13071513","volume":"13","author":"CW Fhu","year":"2021","unstructured":"Fhu CW, Ali A. Dysregulation of the ubiquitin proteasome system in human malignancies: a window for therapeutic intervention. Cancers. 2021;13:1513. https:\/\/doi.org\/10.3390\/cancers13071513.","journal-title":"Cancers"},{"key":"401_CR28","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.Can-13-2033","volume":"74","author":"W Fiskus","year":"2014","unstructured":"Fiskus W, Saba N, Shen M, Ghias M, Liu J, Gupta SD, et al. Auranofin induces lethal oxidative and endoplasmic reticulum stress and exerts potent preclinical activity against chronic lymphocytic leukemia. Cancer Res. 2014;74:2520. https:\/\/doi.org\/10.1158\/0008-5472.Can-13-2033.","journal-title":"Cancer Res"},{"key":"401_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2021.101949","volume":"42","author":"L Freire Boullosa","year":"2021","unstructured":"Freire Boullosa L, Van Loenhout J, Flieswasser T, De Waele J, Hermans C, Lambrechts H, et al. Auranofin reveals therapeutic anticancer potential by triggering distinct molecular cell death mechanisms and innate immunity in mutant p53 non-small cell lung cancer. Redox Biol. 2021;42:101949. https:\/\/doi.org\/10.1016\/j.redox.2021.101949.","journal-title":"Redox Biol"},{"key":"401_CR30","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.2967\/jnumed.110.085100","volume":"52","author":"JE Gains","year":"2011","unstructured":"Gains JE, Bomanji JB, Fersht NL, Sullivan T, D\u2019Souza D, Sullivan KP, et al. 177Lu-DOTATATE molecular radiotherapy for childhood neuroblastoma. J Nucl Med. 2011;52:1041. https:\/\/doi.org\/10.2967\/jnumed.110.085100.","journal-title":"J Nucl Med"},{"key":"401_CR31","doi-asserted-by":"publisher","DOI":"10.4103\/ijnm.IJNM_80_17","author":"P Garg","year":"2017","unstructured":"Garg P, Hazra DK. Conjugation of antibodies with radiogold nanoparticles, as an effector targeting agents in radiobioconjugate cancer therapy: optimized labeling and biodistribution results. Indian J Nucl Med. 2017. https:\/\/doi.org\/10.4103\/ijnm.IJNM_80_17.","journal-title":"Indian J Nucl Med"},{"key":"401_CR32","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.apradiso.2016.10.004","volume":"118","author":"SF Hosseini","year":"2016","unstructured":"Hosseini SF, Sadeghi M, Aboudzadeh MR, Mohseni M. Production and modeling of radioactive gold nanoparticles in Tehran research reactor. Appl Radiat Isot. 2016;118:361. https:\/\/doi.org\/10.1016\/j.apradiso.2016.10.004.","journal-title":"Appl Radiat Isot"},{"key":"401_CR33","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/B978-0-12-816506-5.00017-6","volume-title":"Biomedical applications of nanoparticles","author":"D Ilem-Ozdemir","year":"2019","unstructured":"Ilem-Ozdemir D, Atlihan Gundogdu E, Ekinci M, Ozgenc E, Asikoglu M. Chapter 17 - Nuclear medicine and radiopharmaceuticals for molecular diagnosis. In: Grumezescu AM, editor. Biomedical applications of nanoparticles. Norwich: William Andrew Publishing; 2019. p. 457."},{"key":"401_CR34","volume-title":"Cyclotron-based production of radiopharmaceuticals","author":"International Atomic Energy A","year":"2021","unstructured":"International Atomic Energy A. Cyclotron-based production of radiopharmaceuticals. Vienna: International Atomic Energy Agency (IAEA); 2021."},{"key":"401_CR35","doi-asserted-by":"publisher","first-page":"3588","DOI":"10.1021\/ic00293a029","volume":"27","author":"AA Isab","year":"1988","unstructured":"Isab AA, Shaw CF III, Hoeschele JD, Locke J. Reactions of trimethylphosphine analogs of auranofin with bovine serum albumin. Inorg Chem. 1988;27:3588. https:\/\/doi.org\/10.1021\/ic00293a029.","journal-title":"Inorg Chem"},{"key":"401_CR36","doi-asserted-by":"publisher","first-page":"3407","DOI":"10.1021\/acs.molpharmaceut.4c00138","volume":"21","author":"S Jin","year":"2024","unstructured":"Jin S, Huang J, Dong Y, Hu D, Sun J, Li Z, et al. Ultrastable PLGA-coated 177Lu-microspheres for radioembolization therapy of hepatocellular carcinoma. Mol Pharm. 2024;21:3407. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.4c00138.","journal-title":"Mol Pharm"},{"key":"401_CR37","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1002\/wnan.161","volume":"4","author":"R Kannan","year":"2012","unstructured":"Kannan R, Zambre A, Chanda N, Kulkarni R, Shukla R, Katti K, et al. Functionalized radioactive gold nanoparticles in tumor therapy. Wires Nanomed Nanobiotechnol. 2012;4:42. https:\/\/doi.org\/10.1002\/wnan.161.","journal-title":"Wires Nanomed Nanobiotechnol"},{"key":"401_CR38","doi-asserted-by":"publisher","first-page":"5532","DOI":"10.3390\/molecules27175532","volume":"27","author":"AG Kazakov","year":"2022","unstructured":"Kazakov AG, Julia SB, Taisya YE, Sergey SB, Vadim VK, Omar A, et al. Photonuclear alchemy: obtaining medical isotopes of gold from mercury irradiated on electron accelerators. Molecules. 2022;27:5532. https:\/\/doi.org\/10.3390\/molecules27175532.","journal-title":"Molecules"},{"key":"401_CR39","doi-asserted-by":"publisher","first-page":"1954","DOI":"10.1021\/acs.molpharmaceut.0c00060","volume":"17","author":"JM Kelly","year":"2020","unstructured":"Kelly JM, Ponnala S, Amor-Coarasa A, Zia NA, Nikolopoulou A, Williams C Jr, et al. Preclinical evaluation of a high-affinity sarcophagine-containing PSMA ligand for 64Cu\/67Cu-based theranostics in prostate cancer. Mol Pharm. 2020;17:1954. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.0c00060.","journal-title":"Mol Pharm"},{"key":"401_CR40","doi-asserted-by":"publisher","DOI":"10.1063\/1.4940077","volume":"1704","author":"MU Khandaker","year":"2016","unstructured":"Khandaker MU, Haba H, Kassim HA. Production of radio-gold 199Au for diagnostic and therapeutic applications. AIP Conf Proc. 2016;1704:030008. https:\/\/doi.org\/10.1063\/1.4940077.","journal-title":"AIP Conf Proc"},{"key":"401_CR41","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24119154","volume":"24","author":"OO Krasnovskaya","year":"2023","unstructured":"Krasnovskaya OO, Abramchuck D, Erofeev A, Gorelkin P, Kuznetsov A, Shemukhin A, et al. Recent advances in 64Cu\/67Cu-based radiopharmaceuticals. Int J Mol Sci. 2023;24:9154. https:\/\/doi.org\/10.3390\/ijms24119154.","journal-title":"Int J Mol Sci"},{"key":"401_CR42","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1007\/s10967-014-3816-4","volume":"303","author":"FH Kriel","year":"2015","unstructured":"Kriel FH, Szucs Z, van Staden JA, Bester CJ, Mongane M, Lamprecht S, et al. Biodistribution of a potential chemotherapeutic, dinuclearbisphosphinogold(I) dithiocarbamate, as determined by its 198Au radiolabelled analogue. J Radioanal Nucl Chem. 2015;303:1949. https:\/\/doi.org\/10.1007\/s10967-014-3816-4.","journal-title":"J Radioanal Nucl Chem"},{"key":"401_CR43","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1039\/D4MD00591K","volume":"16","author":"T Kr\u00f6nke","year":"2025","unstructured":"Kr\u00f6nke T, Kopka K, Mamat C. Enhancing the radionuclide theranostic concept through the radiohybrid approach. RSC Med Chem. 2025;16:1856. https:\/\/doi.org\/10.1039\/D4MD00591K.","journal-title":"RSC Med Chem"},{"key":"401_CR44","doi-asserted-by":"publisher","first-page":"414","DOI":"10.3390\/molecules26020414","volume":"26","author":"K Kumar","year":"2021","unstructured":"Kumar K, Ghosh A. Radiochemistry, production processes, labeling methods, and immunoPET imaging pharmaceuticals of iodine-124. Molecules. 2021;26:414. https:\/\/doi.org\/10.3390\/molecules26020414.","journal-title":"Molecules"},{"key":"401_CR45","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1016\/j.nucmedbio.2011.02.007","volume":"38","author":"S Lehenberger","year":"2011","unstructured":"Lehenberger S, Barkhausen C, Cohrs S, Fischer E, Gr\u00fcnberg J, Hohn A, et al. The low-energy \u03b2\u2212 and electron emitter 161Tb as an alternative to 177Lu for targeted radionuclide therapy. Nucl Med Biol. 2011;38:917. https:\/\/doi.org\/10.1016\/j.nucmedbio.2011.02.007.","journal-title":"Nucl Med Biol"},{"key":"401_CR46","doi-asserted-by":"publisher","first-page":"2533","DOI":"10.3390\/biomedicines10102533","volume":"10","author":"M Li","year":"2022","unstructured":"Li M, Zelchan R, Orlova A. The performance of FDA-approved PET imaging agents in the detection of prostate cancer. Biomedicines. 2022;10:2533. https:\/\/doi.org\/10.3390\/biomedicines10102533.","journal-title":"Biomedicines"},{"key":"401_CR47","doi-asserted-by":"publisher","first-page":"5453","DOI":"10.18632\/oncotarget.2113","volume":"5","author":"N Liu","year":"2014","unstructured":"Liu N, Li X, Huang H, Zhao C, Liao S, Yang C, et al. Clinically used antirheumatic agent auranofin is a proteasomal deubiquitinase inhibitor and inhibits tumor growth. Oncotarget. 2014;5:5453. https:\/\/doi.org\/10.18632\/oncotarget.2113.","journal-title":"Oncotarget"},{"key":"401_CR48","doi-asserted-by":"publisher","first-page":"3235","DOI":"10.2147\/ijn.S165289","volume":"13","author":"AC Mart\u00ednez-Torres","year":"2018","unstructured":"Mart\u00ednez-Torres AC, Zarate-Trivi\u00f1o DG, Lorenzo-Anota HY, \u00c1vila-\u00c1vila A, Rodr\u00edguez-Abrego C, Rodr\u00edguez-Padilla C. Chitosan gold nanoparticles induce cell death in HeLa and MCF7 cells through reactive oxygen species production. Int J Nanomed. 2018;13:3235. https:\/\/doi.org\/10.2147\/ijn.S165289.","journal-title":"Int J Nanomed"},{"key":"401_CR49","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.2174\/1381612003399833","volume":"6","author":"E Meral Tayan","year":"2000","unstructured":"Meral Tayan E, Meltem C. Therapeutic radiopharmaceuticals. Curr Pharm des. 2000;6:1085. https:\/\/doi.org\/10.2174\/1381612003399833.","journal-title":"Curr Pharm des"},{"key":"401_CR50","doi-asserted-by":"publisher","first-page":"278","DOI":"10.2214\/AJR.18.19953","volume":"211","author":"ES Mittra","year":"2018","unstructured":"Mittra ES. Neuroendocrine tumor therapy: 177Lu-DOTATATE. AJR Am J Roentgenol. 2018;211:278.","journal-title":"AJR Am J Roentgenol"},{"key":"401_CR51","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.mrgentox.2016.09.003","volume":"809","author":"D Oommen","year":"2016","unstructured":"Oommen D, Dodd NJ, Yiannakis D, Moyeed R, Jha AN. Linking genotoxicity and cytotoxicity with membrane fluidity: a comparative study in ovarian cancer cell lines following exposure to auranofin. Mutat Res\/genet Toxicol Environ Mutagenes. 2016;809:43. https:\/\/doi.org\/10.1016\/j.mrgentox.2016.09.003.","journal-title":"Mutat Res\/genet Toxicol Environ Mutagenes"},{"key":"401_CR52","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.bcp.2017.09.009","volume":"146","author":"F Radenkovic","year":"2017","unstructured":"Radenkovic F, Holland O, Vanderlelie JJ, Perkins AV. Selective inhibition of endogenous antioxidants with auranofin causes mitochondrial oxidative stress which can be countered by selenium supplementation. Biochem Pharmacol. 2017;146:42. https:\/\/doi.org\/10.1016\/j.bcp.2017.09.009.","journal-title":"Biochem Pharmacol"},{"key":"401_CR53","doi-asserted-by":"publisher","DOI":"10.1016\/j.apradiso.2010.05.004","volume":"68","author":"S Rasaneh","year":"2010","unstructured":"Rasaneh S, Rajabi H, Hossein Babaei M, Johari Daha F. Toxicity of trastuzumab labeled 177Lu on MCF7 and SKBr 3 cell lines. Appl Radiat Isot. 2010;68:1964. https:\/\/doi.org\/10.1016\/j.apradiso.2010.05.004.","journal-title":"Appl Radiat Isot"},{"key":"401_CR54","doi-asserted-by":"publisher","DOI":"10.1007\/s40268-015-0083-y","volume":"15","author":"C Roder","year":"2015","unstructured":"Roder C, Thomson MJ. Auranofin: repurposing an old drug for a golden new age. Drugs R D. 2015;15:13. https:\/\/doi.org\/10.1007\/s40268-015-0083-y.","journal-title":"Drugs R D"},{"key":"401_CR55","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2021.102184","volume":"48","author":"P Sabatier","year":"2021","unstructured":"Sabatier P, Beusch CM, Gencheva R, Cheng Q, Zubarev R, Arn\u00e9r ESJ. Comprehensive chemical proteomics analyses reveal that the new TRi-1 and TRi-2 compounds are more specific thioredoxin reductase 1 inhibitors than auranofin. Redox Biol. 2021;48:102184. https:\/\/doi.org\/10.1016\/j.redox.2021.102184.","journal-title":"Redox Biol"},{"key":"401_CR56","doi-asserted-by":"publisher","first-page":"16488","DOI":"10.18632\/oncotarget.4108","volume":"6","author":"MC Sachweh","year":"2015","unstructured":"Sachweh MC, Stafford WC, Drummond CJ, McCarthy AR, Higgins M, Campbell J, et al. Redox effects and cytotoxic profiles of MJ25 and auranofin towards malignant melanoma cells. Oncotarget. 2015;6:16488. https:\/\/doi.org\/10.18632\/oncotarget.4108.","journal-title":"Oncotarget"},{"key":"401_CR57","doi-asserted-by":"publisher","DOI":"10.1016\/j.apradiso.2019.108877","volume":"154","author":"M Sadeghi","year":"2019","unstructured":"Sadeghi M, Aboudzadeh Rovais MR, Zandi N, Moradi M, Yousefi K. Production assessment of non-carrier-added 199Au by (n,\u03b3) reaction. Appl Radiat Isot. 2019;154:108877. https:\/\/doi.org\/10.1016\/j.apradiso.2019.108877.","journal-title":"Appl Radiat Isot"},{"key":"401_CR58","volume-title":"Gold chemistry: applications and future directions in the life sciences","author":"H Schmidbaur","year":"2009","unstructured":"Schmidbaur H. Gold chemistry: applications and future directions in the life sciences. New Jersey: John Wiley & Sons; 2009."},{"key":"401_CR59","doi-asserted-by":"publisher","first-page":"1331364","DOI":"10.3389\/fnume.2024.1331364","volume":"4","author":"AG Shea","year":"2024","unstructured":"Shea AG, Idrissou MB, Torres AI, Chen T, Hernandez R, Morris ZS, et al. Immunological effects of radiopharmaceutical therapy. Front Nucl Med. 2024;4:1331364.","journal-title":"Front Nucl Med"},{"key":"401_CR60","doi-asserted-by":"publisher","first-page":"12426","DOI":"10.1073\/pnas.1121174109","volume":"109","author":"R Shukla","year":"2012","unstructured":"Shukla R, Chanda N, Zambre A, Upendran A, Katti K, Kulkarni RR, et al. Laminin receptor specific therapeutic gold nanoparticles 198AuNP-EGCg) show efficacy in treating prostate cancer. Proc Natl Acad Sci. 2012;109:12426. https:\/\/doi.org\/10.1073\/pnas.1121174109.","journal-title":"Proc Natl Acad Sci"},{"key":"401_CR61","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.112.105148","volume":"53","author":"EB Silberstein","year":"2012","unstructured":"Silberstein EB, Alavi A, Balon HR, Clarke SEM, Divgi C, Gelfand MJ, et al. The SNMMI practice guideline for therapy of thyroid disease with 131I 3.0. J Nucl Med. 2012;53:1633. https:\/\/doi.org\/10.2967\/jnumed.112.105148.","journal-title":"J Nucl Med"},{"key":"401_CR62","doi-asserted-by":"publisher","DOI":"10.1016\/0006-2952(87)90715-5","volume":"36","author":"RM Snyder","year":"1987","unstructured":"Snyder RM, Mirabelli CK, Crooke ST. Cellular interactions of auranofin and a related gold complex with RAW 264.7 macrophages. Biochem Pharmacol. 1987;36:647. https:\/\/doi.org\/10.1016\/0006-2952(87)90715-5.","journal-title":"Biochem Pharmacol"},{"key":"401_CR63","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0048175","volume":"7","author":"A Sobhakumari","year":"2012","unstructured":"Sobhakumari A, Love-Homan L, Fletcher EV, Martin SM, Parsons AD, Spitz DR, et al. Susceptibility of human head and neck cancer cells to combined inhibition of glutathione and thioredoxin metabolism. PLoS ONE. 2012;7:e48175. https:\/\/doi.org\/10.1371\/journal.pone.0048175.","journal-title":"PLoS ONE"},{"key":"401_CR64","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/s13550-022-00947-2","volume":"12","author":"A Stenvall","year":"2022","unstructured":"Stenvall A, Gustafsson J, Larsson E, Roth D, Sundl\u00f6v A, J\u00f6nsson L, et al. Relationships between uptake of [68Ga]Ga-DOTA-TATE and absorbed dose in [177Lu]Lu-DOTA-TATE therapy. EJNMMI Res. 2022;12:75. https:\/\/doi.org\/10.1186\/s13550-022-00947-2.","journal-title":"EJNMMI Res"},{"key":"401_CR65","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1152\/ajplegacy.1960.199.1.67","volume":"199","author":"HA Swartz","year":"1960","unstructured":"Swartz HA, Christian JE, Andrews FN. Distribution of sulfur-35- and gold-198-labeled gold thioglucose in mice. Am J Physiol-Legacy Content. 1960;199:67. https:\/\/doi.org\/10.1152\/ajplegacy.1960.199.1.67.","journal-title":"Am J Physiol-Legacy Content"},{"key":"401_CR66","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1007\/s10534-012-9578-y","volume":"25","author":"P Szyma\u0144ski","year":"2012","unstructured":"Szyma\u0144ski P, Fr\u0105czek T, Markowicz M, Mikiciuk-Olasik E. Development of copper based drugs, radiopharmaceuticals and medical materials. Biometals. 2012;25:1089. https:\/\/doi.org\/10.1007\/s10534-012-9578-y.","journal-title":"Biometals"},{"key":"401_CR67","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1524\/ract.92.4.223.35588","volume":"92","author":"F T\u00e1rk\u00e1nyi","year":"2004","unstructured":"T\u00e1rk\u00e1nyi F, Hermanne A, Tak\u00e1cs S, Shubin YN, Dityuk AI. Cross sections for production of the therapeutic radioisotopes 198Au and 199Au in proton and deuteron induced reactions on 198Pt. Radiochim Acta. 2004;92:223. https:\/\/doi.org\/10.1524\/ract.92.4.223.35588.","journal-title":"Radiochim Acta"},{"key":"401_CR68","doi-asserted-by":"publisher","first-page":"18949","DOI":"10.18632\/oncotarget.24855","volume":"9","author":"PL Tseng","year":"2018","unstructured":"Tseng PL, Chen CW, Hu KH, Cheng HC, Lin YH, Tsai WH, et al. The decrease of glycolytic enzyme hexokinase 1 accelerates tumor malignancy via deregulating energy metabolism but sensitizes cancer cells to 2-deoxyglucose inhibition. Oncotarget. 2018;9:18949. https:\/\/doi.org\/10.18632\/oncotarget.24855.","journal-title":"Oncotarget"},{"key":"401_CR69","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1002\/9780470132579.ch17","volume":"26","author":"R Uson","year":"1989","unstructured":"Uson R, Laguna A, Laguna M, Briggs DA, Murray HH, Fackler JP Jr. (Tetrahydrothiophene)Gold(I) or Gold(III) complexes. Inorg Synth. 1989;26:85\u201391.","journal-title":"Inorg Synth"},{"key":"401_CR70","doi-asserted-by":"publisher","DOI":"10.2174\/1874471011104040283","volume":"4","author":"G Vaidyanathan","year":"2011","unstructured":"Vaidyanathan G, Zalutsky MR. Applications of 211At and 223Ra in targeted alpha-particle radiotherapy. Curr Radiopharmaceuticalse. 2011;4:283. https:\/\/doi.org\/10.2174\/1874471011104040283.","journal-title":"Curr Radiopharmaceuticalse"},{"key":"401_CR71","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1021\/acsmaterialsau.2c00075","volume":"3","author":"A Vihervaara","year":"2023","unstructured":"Vihervaara A, Hatanp\u00e4\u00e4 T, Nieminen H-E, Mizohata K, Chundak M, Ritala M. Reductive thermal atomic layer deposition process for gold. ACS Mater Au. 2023;3:206. https:\/\/doi.org\/10.1021\/acsmaterialsau.2c00075.","journal-title":"ACS Mater Au"},{"key":"401_CR72","doi-asserted-by":"publisher","first-page":"82832","DOI":"10.1039\/C6RA15407G","volume":"6","author":"KV Vimalnath","year":"2016","unstructured":"Vimalnath KV, Chakraborty S, Dash A. Reactor production of no-carrier-added 199Au for biomedical applications. RSC Adv. 2016;6:82832. https:\/\/doi.org\/10.1039\/C6RA15407G.","journal-title":"RSC Adv"},{"key":"401_CR73","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1039\/C6GC02908F","volume":"19","author":"J Wang","year":"2017","unstructured":"Wang J, Mi X, Wang J, Yang Y. An efficient approach to chloro(organophosphine) gold(I) complexes for the synthesis of auranofin. Green Chem. 2017;19:634. https:\/\/doi.org\/10.1039\/C6GC02908F.","journal-title":"Green Chem"},{"key":"401_CR74","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1021\/acs.organomet.3c00016","volume":"42","author":"JA Werra","year":"2023","unstructured":"Werra JA, Wurst K, Wilm LB, L\u00f6we P, R\u00f6thel MB, Dielmann F. 1,2,5-Trimethylpyrrolyl phosphines: a class of strongly donating arylphosphines. Organometallics. 2023;42:597. https:\/\/doi.org\/10.1021\/acs.organomet.3c00016.","journal-title":"Organometallics"},{"key":"401_CR75","doi-asserted-by":"publisher","first-page":"2172","DOI":"10.1021\/ja0457718","volume":"127","author":"GH Woehrle","year":"2005","unstructured":"Woehrle GH, Brown LO, Hutchison JE. Thiol-functionalized, 1.5-nm gold nanoparticles through ligand exchange reactions: scope and mechanism of ligand exchange. J Am Chem Soc. 2005;127:2172. https:\/\/doi.org\/10.1021\/ja0457718.","journal-title":"J Am Chem Soc"},{"key":"401_CR76","doi-asserted-by":"publisher","DOI":"10.1097\/mnm.0000000000001592","volume":"43","author":"KK Wong","year":"2022","unstructured":"Wong KK, Frey KA, Niedbala J, Kaza RK, Worden FP, Fitzpatrick KJ, et al. Differences in tumor-to-normal organ SUV ratios measured with 68Ga-DOTATATE PET compared with 177Lu-DOTATATE SPECT in patients with neuroendocrine tumors. Nucl Med Commun. 2022;43:892. https:\/\/doi.org\/10.1097\/mnm.0000000000001592.","journal-title":"Nucl Med Commun"},{"key":"401_CR77","doi-asserted-by":"publisher","first-page":"11748","DOI":"10.1039\/D4SC02851A","volume":"15","author":"JL Wood","year":"2024","unstructured":"Wood JL, Ghosh S, Houston ZH, Fletcher NL, Humphries J, Mardon K, et al. A first-in-class dual-chelator theranostic agent designed for use with imaging-therapy radiometal pairs of different elements. Chem Sci. 2024;15:11748. https:\/\/doi.org\/10.1039\/D4SC02851A.","journal-title":"Chem Sci"},{"key":"401_CR78","doi-asserted-by":"publisher","first-page":"3492","DOI":"10.1016\/j.cclet.2022.01.007","volume":"33","author":"M Wu","year":"2022","unstructured":"Wu M, Shi K, Huang R, Liu C, Yin L, Yong W, et al. Facile preparation of 177Lu-microspheres for hepatocellular carcinoma radioisotope therapy. Chin Chem Lett. 2022;33:3492. https:\/\/doi.org\/10.1016\/j.cclet.2022.01.007.","journal-title":"Chin Chem Lett"},{"key":"401_CR79","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2021.108272","volume":"101","author":"M Yamashita","year":"2021","unstructured":"Yamashita M. Auranofin: past to present, and repurposing. Int Immunopharmacol. 2021;101:108272. https:\/\/doi.org\/10.1016\/j.intimp.2021.108272.","journal-title":"Int Immunopharmacol"},{"key":"401_CR80","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2024.103245","volume":"75","author":"M Yang","year":"2024","unstructured":"Yang M, Liu J, Li J, Wen S, Hu Y, Lu W, et al. The rheumatoid arthritis drug auranofin exerts potent anti-lymphoma effect by stimulating TXNRD-mediated ROS generation and inhibition of energy metabolism. Redox Biol. 2024;75:103245. https:\/\/doi.org\/10.1016\/j.redox.2024.103245.","journal-title":"Redox Biol"},{"key":"401_CR81","doi-asserted-by":"publisher","first-page":"546","DOI":"10.3892\/or.2015.4382","volume":"35","author":"BR You","year":"2016","unstructured":"You BR, Park WH. Auranofin induces mesothelioma cell death through oxidative stress and GSH depletion. Oncol Rep. 2016;35:546. https:\/\/doi.org\/10.3892\/or.2015.4382.","journal-title":"Oncol Rep"},{"key":"401_CR82","doi-asserted-by":"publisher","first-page":"4676","DOI":"10.1021\/acs.molpharmaceut.3c00414","volume":"20","author":"K \u017belechowska-Matysiak","year":"2023","unstructured":"\u017belechowska-Matysiak K, Salvanou E-A, Bouziotis P, Budlewski T, Bilewicz A, Majkowska-Pilip A. Improvement of the effectiveness of HER2+ cancer therapy by use of doxorubicin and trastuzumab modified radioactive gold nanoparticles. Mol Pharm. 2023;20:4676. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.3c00414.","journal-title":"Mol Pharm"},{"key":"401_CR83","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.biochi.2019.03.015","volume":"162","author":"X Zhang","year":"2019","unstructured":"Zhang X, Selvaraju K, Saei AA, D\u2019Arcy P, Zubarev RA, Arn\u00e9r ESJ, et al. Repurposing of auranofin: thioredoxin reductase remains a primary target of the drug. Biochimie. 2019;162:46. https:\/\/doi.org\/10.1016\/j.biochi.2019.03.015.","journal-title":"Biochimie"},{"key":"401_CR84","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1002\/adhm.201500992","volume":"5","author":"Y Zhao","year":"2016","unstructured":"Zhao Y, Pang B, Luehmann H, Detering L, Yang X, Sultan D, et al. Gold nanoparticles doped with (199) Au atoms and their use for targeted cancer imaging by SPECT. Adv Healthc Mater. 2016;5:928. https:\/\/doi.org\/10.1002\/adhm.201500992.","journal-title":"Adv Healthc Mater"}],"container-title":["EJNMMI Radiopharmacy and Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41181-025-00401-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s41181-025-00401-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41181-025-00401-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T12:44:17Z","timestamp":1762865057000},"score":1,"resource":{"primary":{"URL":"https:\/\/ejnmmipharmchem.springeropen.com\/articles\/10.1186\/s41181-025-00401-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,5]]},"references-count":84,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["401"],"URL":"https:\/\/doi.org\/10.1186\/s41181-025-00401-3","relation":{},"ISSN":["2365-421X"],"issn-type":[{"value":"2365-421X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,5]]},"assertion":[{"value":"7 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Sarah Spreckelmeyer serves as an Associate Editor of\n                      EJNMMI Radiopharmacy and Chemistry\n                      . All other authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"71"}}